GlobeNewswire Inc.··Okyo Pharma LimitedOKYO Pharma Prices $20M Share Offering to Fund Clinical Development
OKYO Pharma prices $20M share offering to fund clinical development of urcosimod for neuropathic corneal pain treatment, advancing Phase 2b/3 trial.
OKYOPIPRclinical developmentpublic offering